UBS Group
PCRX icon

UBS Group’s Pacira BioSciences PCRX Stock Holding History

UBS Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-200
Closed -$18K – 9211
2014
Q4 		$18K Buy
+200
New +$18.9K ﹤0.01% 7801

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's PCRX Position: Q2 2026 in Review

UBS Group increased its Pacira BioSciences (PCRX) stake by 64% in Q2 2026, buying an estimated $8.47M and bringing the position to 920,217 shares worth $23.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2522.

UBS Group first reported a position in PCRX in Q4 2014 and has held it in 47 quarters since. The position peaked at $25.9M in Q4 2024. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • UBS Group held 920,217 shares of Pacira BioSciences worth $23.3M as of Q2 2026.
  • UBS Group bought 358,177 Pacira BioSciences shares in Q2 2026, an estimated $8.47M.
  • Pacira BioSciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2522 holding.
  • UBS Group first reported a position in Pacira BioSciences in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Pacira BioSciences position peaked at $25.9M in Q4 2024.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.